The four-metabolite panel (α-ketoglutarate, succinic acid, tryptamine, and amino butyric acid) may provide experimental basis for further mechanistic research and therapeutic development and offer peripheral evidence supporting the core position of GABAergic dysfunction in schizophrenia.
Abstract
Objective To investigate peripheral metabolic alterations in patients with schizophrenia using a two-stage metabolomic workflow of untargeted analysis and targeted re-analysis,explore the associated metabolic pathways, identify potential peripheral metabolic biomarkers, and elucidate the underlying metabolic dysregulation mechanisms. Methods Plasma samples were collected from 24 schizophrenia patients and 10 healthy controls for non-derivatized targeted metabolomics analysis. Differential metabolites were identified and visualized using box plots. Hierarchical clustering analysis was performed to evaluate expression pattern differences across samples, and KEGG pathway enrichment analysis was conducted to map the involved biological pathways. False discovery rate (FDR) correction was applied for multiple comparisons. Results Among the 21 quantified metabolites, four exhibited significant differences after FDR correction (FDR < 0.05). α-Ketoglutarate was significantly elevated in the patient group, whereas succinic acid, tryptamine, and amino butyric acid were significantly reduced. The opposite variations of α-ketoglutarate and succinic acid suggest a peripheral TCA cycle metabolic bottleneck. Hierarchical clustering based on these four metabolites effectively distinguished patients from healthy controls. KEGG enrichment demonstrated that these metabolites converged predominantly on amino acid metabolism, energy metabolism, and most notably the GABAergic synapse pathway, offering peripheral evidence supporting the core position of GABAergic dysfunction in schizophrenia. Conclusion Schizophrenia patients display significant peripheral metabolic disturbances characterized by dysregulated amino acid metabolism, synaptic transmission abnormalities, and energy metabolism imbalance. The four-metabolite panel (α-ketoglutarate, succinic acid, tryptamine, and amino butyric acid) may provide experimental basis for further mechanistic research and therapeutic development.
This exploratory study integrates pilot-scale metabolomics with genetic analyses to identify candidate metabolic signals and inflammatory pathways linked to PD and indicated that SULT1A1 may partially mediate the association between 3-phenylpropionylglycine and PD.
PTZ-induced kindling was associated with marked plasma metabolic alterations involving amino acid-, tryptophan-, and lipid-related pathways, which supports the broader relevance of metabolic dysregulation to epilepsy, while the mechanistic roles and biomarker potential of individual metabolites require independent vali...
Juan Ren, Fu-Li Wang, Zi-Jian Li et al.· Frontiers in Neuroscience· 0 citations
Sleep disorders are common and significantly impact metabolic regulation, but the overarching blood metabolomic characteristics and how drugs for these disorders affect metabolism have not been adequately described. Blood plasma from three distinct cohorts-healthy individuals, sleep disorder patients (SDP), and those u...
Anwar Abdurahman, Ailiyaer Yasheng, Aikelidan Abulajiang et al.· Frontiers in Pharmacology· 0 citations
Serum levels of five DEMs (Glu, Pro, Orn, Cit, Cit, and Arg) are closely linked to ALD-related metabolic dysregulation; they serve as potential indicators of ALD progression and provide valuable insights for the clinical staging and targeted intervention of ALD.
Jie-Sen Lu, Li Zhao, Tian-Yi Zhu et al.· Egyptian Liver Journal· 0 citations
Untargeted metabolomics enables identification of metabolically perturbed pathways during the acute phase of KD, and L-tyrosine, L-tryptophan, glutamine, histidine, histamine, and taurocholic acid may serve as candidate biomarkers for acute phase of KD.
Han-Qi Dai, Qian-Wen Wang, Yi Zhan· Frontiers in Medicine· 0 citations